Serum Erwinia asparaginase trough levels ≥20 U/L, ≥50 U/L, or ≥100 U/L
| . | Erwinase activity median (range) . | Samples* . | Patients (n = 57) . | ||||
|---|---|---|---|---|---|---|---|
| ≥20 . | ≥50 . | ≥100 . | ≥20 . | ≥50 . | ≥100 . | ||
| First 2 weeks of Erwinia asparaginase therapy | |||||||
| 3 times per week | 157 (11-913) | 98% | 85% | 65% | 95%† | 60%† | 32%† |
| At least 1 sample above 20, 50, or 100 U/L | 100% | 100% | 96% | ||||
| Week 6 to week 30 of Erwinia asparaginase therapy | |||||||
| 3 times per week, 48-h interval | 182 (22-737) | 100% | 94% | 77% | 100%† | 87%† | 47%† |
| At least 1 sample above 20, 50, or 100 U/L | 100% | 100% | 100% | ||||
| 2 times per week, 72-h interval | 83 (14-908) | 96% | 86% | 34% | 95%† | 68%† | 11%† |
| At least 1 sample above 20, 50, or 100 U/L | 100% | 100% | 68% | ||||
| . | Erwinase activity median (range) . | Samples* . | Patients (n = 57) . | ||||
|---|---|---|---|---|---|---|---|
| ≥20 . | ≥50 . | ≥100 . | ≥20 . | ≥50 . | ≥100 . | ||
| First 2 weeks of Erwinia asparaginase therapy | |||||||
| 3 times per week | 157 (11-913) | 98% | 85% | 65% | 95%† | 60%† | 32%† |
| At least 1 sample above 20, 50, or 100 U/L | 100% | 100% | 96% | ||||
| Week 6 to week 30 of Erwinia asparaginase therapy | |||||||
| 3 times per week, 48-h interval | 182 (22-737) | 100% | 94% | 77% | 100%† | 87%† | 47%† |
| At least 1 sample above 20, 50, or 100 U/L | 100% | 100% | 100% | ||||
| 2 times per week, 72-h interval | 83 (14-908) | 96% | 86% | 34% | 95%† | 68%† | 11%† |
| At least 1 sample above 20, 50, or 100 U/L | 100% | 100% | 68% | ||||
The table is based on 57 patients without allergy to Erwinia asparaginase. The 2 patients with clinical allergy to Erwinia asparaginase were removed from this group. The table shows the data of the period week 6 to week 30 of Erwinia asparaginase therapy of 142 samples of 38 patients who continued infusions 3 times per week after the first 2 weeks of Erwinia asparaginase therapy and the data of 71 samples of 19 patients who were switched to infusions 2 times per week after the first 2 weeks of therapy. h, hour.
For first 2 weeks of Erwinia asparaginase therapy, n = 231 samples; for week 6 to week 30 of Erwinia asparaginase therapy, n = 213 samples.
Number of patients with all samples above 20 U/L, 50 U/L, or 100 U/L.